We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates
Read MoreHide Full Article
Headquartered in Deerfield, Illinois, Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #2 (Buy) but that could change following its first-quarter 2019 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here) We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 76 cents per share beat the Zacks Consensus Estimate of 68 cents and increased from 70 cents from the year-ago quarter.
Revenues: Baxter posted worldwide sales of $2.63 billion, beating the Zacks Consensus Estimate for revenues of $2.62 billion. At constant currency (cc), revenues increased almost 2% on a year-over-year basis.
Key Stats: Renal Products delivered revenues worth $851 million, down 1.9% from the year-ago quarter. Pharmaceuticals delivered revenues worth $509 million, up 2.6% year over year and Advanced Surgery revenues totaled $198 million, up 8.8% from the year-ago quarter.
Major Factors: Diversified portfolio, increased focus on high-value innovation and a continued focus on operational excellence drove the first-quarter 2019 results.
For full-year 2019, Baxter expects revenue growth to be approximately 2-3% at cc.
Adjusted earnings for 2019 are expected in the band of $3.27 to $3.35 per share and for second quarter of 2019 adjusted earnings are projected to be in the range of 80-82 cents per share.
Stock Price: Following the earnings release, share price inched up 0.03% at $76.30 in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
Image: Bigstock
Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates
Headquartered in Deerfield, Illinois, Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #2 (Buy) but that could change following its first-quarter 2019 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here) We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 76 cents per share beat the Zacks Consensus Estimate of 68 cents and increased from 70 cents from the year-ago quarter.
Revenues: Baxter posted worldwide sales of $2.63 billion, beating the Zacks Consensus Estimate for revenues of $2.62 billion. At constant currency (cc), revenues increased almost 2% on a year-over-year basis.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote
Key Stats: Renal Products delivered revenues worth $851 million, down 1.9% from the year-ago quarter. Pharmaceuticals delivered revenues worth $509 million, up 2.6% year over year and Advanced Surgery revenues totaled $198 million, up 8.8% from the year-ago quarter.
Major Factors: Diversified portfolio, increased focus on high-value innovation and a continued focus on operational excellence drove the first-quarter 2019 results.
For full-year 2019, Baxter expects revenue growth to be approximately 2-3% at cc.
Adjusted earnings for 2019 are expected in the band of $3.27 to $3.35 per share and for second quarter of 2019 adjusted earnings are projected to be in the range of 80-82 cents per share.
Stock Price: Following the earnings release, share price inched up 0.03% at $76.30 in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>